GlassScriptPhysician profile
Ajay Berdia
NPI 1801891908
$9,901.72
in general payments reported to CMS, 2019-2025
39 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $344 · 2021: $1,068 · 2022: $778 · 2023: $1,340 · 2024: $2,100 · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,725 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,724.92 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,492.11 | 2019 | |
| Abbvie INC. | $1,245.34 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Alkermes, INC. | $999.26 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $691.71 | 2022-2025 | Cobenfy |
| Alexion Pharmaceuticals, INC. | $670.86 | 2020-2024 | Ultomiris |
| Ucb, INC. | $592.31 | 2023-2024 | Nayzilam, Fintepla, Rystiggo |
| Lundbeck LLC | $494.90 | 2022-2025 | Vyepti |
| Eisai INC. | $310.77 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $302.85 | 2024-2025 | Crexont, Ongentys |
| Jazz Pharmaceuticals INC. | $290.51 | 2023-2024 | Epidiolex |
| Indivior INC. | $263.20 | 2019-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $227.00 | 2019-2025 | |
| Acorda Therapeutics, INC | $222.76 | 2019 | |
| Neurelis, INC. | $212.62 | 2020-2024 | Valtoco |
| Lilly USA, LLC | $194.27 | 2025 | Kisunla |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $167.92 | 2019-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $151.96 | 2021-2025 | Percept PC Brainsense |
| Acadia Pharmaceuticals INC | $125.60 | 2021 | |
| Supernus Pharmaceuticals, INC. | $125.01 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2022 | |
| Amgen INC. | $124.97 | 2025 | |
| Axsome Therapeutics, INC. | $124.89 | 2025 | Sunosi |
| Janssen Pharmaceuticals, INC | $123.41 | 2019-2024 | Xarelto |
| Medicomp INC | $120.76 | 2024 | Telepatch Cardiac Monitor |
| Mylan Specialty L.P. | $114.77 | 2023 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $65.27 | 2025 | |
| Sk Life Science, INC. | $47.14 | 2022-2024 | |
| Pfizer INC. | $41.46 | 2023 | |
| Melinta Therapeutics, LLC | $39.59 | 2024 | Orbactiv, Kimyrsa |
| Zogenix INC. | $28.16 | 2021 | |
| Neuropace, INC. | $23.79 | 2024 | |
| Chiesi USA, INC. | $21.21 | 2025 | Kengreal, Cleviprex |
| Csl Behring | $20.00 | 2023 | Kcentra |
| Allergan, INC. | $19.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2023 | Jardiance |
| Greenwich Biosciences, INC. | $17.90 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2025 | Caldolor |
| Endo USA, INC. | $15.38 | 2025 | Aveed |
| Medtronic USA, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Berdia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.